Open AccessTislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
Author(s) -
Jie Wang,
Shun Lü,
Xinmin Yu,
Yanping Hu,
Yuping Sun,
Zhijie Wang,
Jun Zhao,
Yan Yu,
Chunhong Hu,
Kunyu Yang,
Guosheng Feng,
Kejing Ying,
Wu Zhuang,
Jianying Zhou,
Jingxun Wu,
S. Leaw,
Jing Zhang,
Xiao Lin,
Liang Liang,
g Yang
Publication year - 2021
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2021.0366
Subject(s) - medicine , carboplatin , tolerability , chemotherapy , lung cancer , oncology , paclitaxel , response evaluation criteria in solid tumors , clinical endpoint , adverse effect , surgery , gastroenterology , randomized controlled trial , phases of clinical research , cisplatin
This study demonstrates that tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS) in patients with advanced squamous non-small-cell lung cancer (sq-NSCLC).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom